Aegerion Pharmaceuticals (AEGR) 43.43 $AEGR
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Aegerion Shares Up on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 3:30PM CDT
Aegerion Pharma's shares gained 5.7% immediately after the start of a phase III study in Japan to evaluate Juxtapid in HoFH patients.
Today’s Top Health Care Stories: Intuitive Surgical, Aegerion, and Gilead Sciences
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 09, 8:25AM CDT
Lets take a look at three stocks -- Intuitive Surgical , Aegerion , and Gilead Sciences -- which could cause a lot of market buzz across the health care sector this Wednesday morning. Intuitive Surgical's gloomy first quarter...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
GlobeNewswire - Wed Apr 09, 8:22AM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with debilitating rare diseases, today announced that patient enrollment has been initiated in Japan in a clinical trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) in Japanese patients with homozygous familial hypercholesterolemia (HoFH). Last year, Aegerion received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for lomitapide.
Aegerion Pharmaceuticals awards stock options at USD47.11 per share under inducement programme
M2 - Tue Apr 08, 6:52AM CDT
Biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Monday the grant of stock options to purchase an aggregate of 31,620 shares of common stock under the inducement stock option programme.
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Mon Apr 07, 3:36PM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on April 1, 2014, Aegerion granted stock options to purchase an aggregate of 31,620 shares of common stock to nine new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $47.11, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Rare LDL Cholesterol Disease Sufferers May Soon Have a New Drug
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 12:05PM CDT
An increasing number of pharmaceutical companies in recent years have focused some or all of their research on rare and orphan diseases. Although these diseases have relatively small patient populations, and the research that goes into drug...
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014 -- AEGR
Business Wire - Tue Mar 11, 12:05PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"
(Nasdaq: AEGR) securities between March 15, 2012 and January 9, 2014.
Technical Pointers - Top Gainers: CEL-SCI, RadioShack, Penn West Petroleum, and Aegerion Pharma
PR Newswire - Mon Mar 10, 12:56PM CDT
On Friday, March 07, 2014, the US markets saw a mixed sentiment, with the NASDAQ Composite closing at 4,336.22, down 0.37%, the Dow Jones Industrial Average ending the session at 16,452.72, up 0.19% and the S&P 500 edging 0.05% higher to finish the trading session at 1,878.04. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Materials and Information Technology sectors. A number of stocks saw large movements, including Cel-Sci Corporation (NYSE MKT: CVM), RadioShack Corporation (NYSE: RSH), Penn West Petroleum Ltd (NYSE: PWE), and Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), which were amongst the top gainers for the session. Free research on these four companies can be accessed at:
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Aegerion Pharmaceuticals awards stock options to new employees
M2 - Mon Mar 10, 7:52AM CDT
US-based biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Friday the grant of stock options to purchase an aggregate of 51,750 common shares to 16 new employees under its inducement stock option programme.
3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aegerion Pharmaceuticals, Inc. to Contact Brower Piven Before the March 17, 2014 Lead Plaintiff Deadline -- AEGR
GlobeNewswire - Fri Mar 07, 6:17PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company" (Nasdaq:AEGR) securities during the period between March 15, 2012 and January 9, 2014, inclusive (the "Class Period" .
Profit from Orphan Drugs: 3 Choices (Revised) - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 07, 1:33PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
LEAD PLAINTIFF DEADLINE: The Alexander Firm P.C. Announces Upcoming Lead Plaintiff Deadline of March 17, 2014, Concerning Class Actions Against Aegerion Pharmaceuticals, Inc.
Business Wire - Thu Mar 06, 7:32PM CST
The Alexander Firm P.C., A Professional Law Corporation, reminds investors who purchased or acquired shares of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company" (NASDAQ: AEGR) between March 15, 2012 and January 9, 2014 (the "Class Period" that the deadline of March 17, 2014, is quickly approaching to move for Lead Plaintiff in the securities class actions filed on behalf of investors against the Company and certain of its officers.
The Zacks Analyst Blog Highlights:Sanofi, Aegerion Pharmaceuticals, Shire, Amgen and Biogen Idec
PR Newswire - Thu Mar 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report) and Biogen Idec Inc. (Nasdaq:BIIB-Free Report).
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Aegerion Shares Up on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 3:30PM CDT
Aegerion Pharma's shares gained 5.7% immediately after the start of a phase III study in Japan to evaluate Juxtapid in HoFH patients.
Today’s Top Health Care Stories: Intuitive Surgical, Aegerion, and Gilead Sciences
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 09, 8:25AM CDT
Lets take a look at three stocks -- Intuitive Surgical , Aegerion , and Gilead Sciences -- which could cause a lot of market buzz across the health care sector this Wednesday morning. Intuitive Surgical's gloomy first quarter...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
GlobeNewswire - Wed Apr 09, 8:22AM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with debilitating rare diseases, today announced that patient enrollment has been initiated in Japan in a clinical trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) in Japanese patients with homozygous familial hypercholesterolemia (HoFH). Last year, Aegerion received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for lomitapide.
Aegerion Pharmaceuticals awards stock options at USD47.11 per share under inducement programme
M2 - Tue Apr 08, 6:52AM CDT
Biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Monday the grant of stock options to purchase an aggregate of 31,620 shares of common stock under the inducement stock option programme.
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Mon Apr 07, 3:36PM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on April 1, 2014, Aegerion granted stock options to purchase an aggregate of 31,620 shares of common stock to nine new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $47.11, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Rare LDL Cholesterol Disease Sufferers May Soon Have a New Drug
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 12:05PM CDT
An increasing number of pharmaceutical companies in recent years have focused some or all of their research on rare and orphan diseases. Although these diseases have relatively small patient populations, and the research that goes into drug...
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014 -- AEGR
Business Wire - Tue Mar 11, 12:05PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"
(Nasdaq: AEGR) securities between March 15, 2012 and January 9, 2014. Technical Pointers - Top Gainers: CEL-SCI, RadioShack, Penn West Petroleum, and Aegerion Pharma
PR Newswire - Mon Mar 10, 12:56PM CDT
On Friday, March 07, 2014, the US markets saw a mixed sentiment, with the NASDAQ Composite closing at 4,336.22, down 0.37%, the Dow Jones Industrial Average ending the session at 16,452.72, up 0.19% and the S&P 500 edging 0.05% higher to finish the trading session at 1,878.04. During the session gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Materials and Information Technology sectors. A number of stocks saw large movements, including Cel-Sci Corporation (NYSE MKT: CVM), RadioShack Corporation (NYSE: RSH), Penn West Petroleum Ltd (NYSE: PWE), and Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), which were amongst the top gainers for the session. Free research on these four companies can be accessed at:
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Aegerion Pharmaceuticals awards stock options to new employees
M2 - Mon Mar 10, 7:52AM CDT
US-based biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Friday the grant of stock options to purchase an aggregate of 51,750 common shares to 16 new employees under its inducement stock option programme.
3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aegerion Pharmaceuticals, Inc. to Contact Brower Piven Before the March 17, 2014 Lead Plaintiff Deadline -- AEGR
GlobeNewswire - Fri Mar 07, 6:17PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"
(Nasdaq:AEGR) securities during the period between March 15, 2012 and January 9, 2014, inclusive (the "Class Period" . Profit from Orphan Drugs: 3 Choices (Revised) - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 07, 1:33PM CST
The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
LEAD PLAINTIFF DEADLINE: The Alexander Firm P.C. Announces Upcoming Lead Plaintiff Deadline of March 17, 2014, Concerning Class Actions Against Aegerion Pharmaceuticals, Inc.
Business Wire - Thu Mar 06, 7:32PM CST
The Alexander Firm P.C., A Professional Law Corporation, reminds investors who purchased or acquired shares of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company"
(NASDAQ: AEGR) between March 15, 2012 and January 9, 2014 (the "Class Period" that the deadline of March 17, 2014, is quickly approaching to move for Lead Plaintiff in the securities class actions filed on behalf of investors against the Company and certain of its officers. The Zacks Analyst Blog Highlights:Sanofi, Aegerion Pharmaceuticals, Shire, Amgen and Biogen Idec
PR Newswire - Thu Mar 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report) and Biogen Idec Inc. (Nasdaq:BIIB-Free Report).
